Takeda obtains expanded FDA approval for Gammagard Liquid ERC
Gammagard Liquid ERC with IgA content of less than or equal to 2µg/mL in a 10% solution is intended for people with primary immunodeficiency (PI).
A leading resource for the Pharmaceutical industry since 2002
Gammagard Liquid ERC with IgA content of less than or equal to 2µg/mL in a 10% solution is intended for people with primary immunodeficiency (PI).
Give your business an edge with our leading industry insights.